Clinical Trials Browser

Phase 1/2 × INDUSTRY × sugemalimab × Clear all

NCT04194801 2023-02-06

A Phase Ib/II Study of Fisogatinib(BLU-554) in Subjects With Hepatocellular Carcinoma

Phase 1/2 Completed

26 enrolled 31 charts

Gastrointestinal

Carcinoma, Hepatocellular